Abies Alba Leafy Twig Beef Lung Bos Taurus Nasal M
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Abies Alba Leafy Twig Beef Lung Bos Taurus Nasal M
- Multi-Component Homeopathic Combination: Insufficient Data for Repurposing Analysis
Multi-Component Homeopathic Combination: Insufficient Data for Repurposing Analysis
One-Sentence Summary
This candidate is a complex 11-component combination product containing homeopathic botanicals, bovine biological extracts, and iron compounds (including Echinacea, Bryonia alba, Eupatorium perfoliatum, Sage, and Thyroid bovine, among others). The TxGNN model returned no predicted indications for this compound due to the absence of a DrugBank ID and the inability to map the multi-component mixture to the knowledge graph. With 0 clinical trials and 0 publications linkable to this specific combination, and no active US market authorizations, the current evidence base is insufficient to support repurposing analysis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available, and no TxGNN repurposing predictions were generated for this compound. The query pipeline could not resolve any of the 11 components to a DrugBank ID, which is a prerequisite for knowledge-graph traversal and deep-learning scoring.
The ingredient profile — Echinacea, Eupatorium perfoliatum, Bryonia alba, Plantago major, Sage, and Abies alba — is consistent with classical European homeopathic or phytotherapeutic preparations typically indicated for upper respiratory tract infections or flu-like syndromes. The bovine biological components (beef lung, nasal mucosa, thyroid) suggest an organo-therapeutic or isopathic formulation philosophy. The iron compounds (ferrosoferric phosphate, ferrous disulfide) are sometimes used in homeopathic potencies for constitutional or hematopoietic support.
However, because the product is evaluated as a single multi-component INN string rather than individual resolved components, the TxGNN pipeline cannot generate meaningful cross-indication predictions. Individual ingredients (e.g., Echinacea) may have independent repurposing signals, but those cannot be attributed to this combination without disaggregation and individual mapping.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No US market authorizations on record for this compound.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline could not process this candidate due to the absence of a resolvable DrugBank ID and the multi-component INN structure, resulting in zero predictions, zero evidence links, and no regulatory footprint to anchor a repurposing case. There is no actionable signal to evaluate at this time.
To proceed, the following is needed:
- Component disaggregation: Separate each of the 11 ingredients and query them individually through the TxGNN pipeline to identify per-component repurposing signals.
- DrugBank ID resolution: Map individual ingredients (especially Echinacea, Bryonia alba, Eupatorium perfoliatum, Plantago major, and Sage) to their respective DrugBank entries to enable KG-based predictions.
- Product identity clarification: Confirm the brand name and intended indication of this combination product (the ingredient profile resembles products such as Engystol or similar homeopathic flu preparations) to anchor a targeted literature search.
- MOA documentation: Retrieve mechanism-of-action data for any ingredients that have established pharmacological profiles (e.g., Echinacea’s immunomodulatory properties).
- Safety data retrieval: Download and parse the package insert PDF from the originating regulatory authority to populate warnings, contraindications, and drug interaction data.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.